Secondary Outcomes
Three months after PPCI, secondary outcomes including in-hospital and
out-of-hospital death due to cardiovascular diseases, re-infarction,
cerebrovascular events, major bleeding, minor bleeding, TVR and TLR were
investigated (Table 4). Investigations showed that the rate of
re-infarction and performing TLR was significantly lower in the group
that received Eptifibatide infusion, while there was no significant
difference of death due to cardiovascular diseases, cerebrovascular
events, major and minor bleeding and TVR between two groups.